SSR1

Across TCGA pan-cancer cohorts, SSR1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SSR1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where SSR1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SSR1 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where SSR1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SSR1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.466	<.001	10	view →
LSCC	Female	All	+0.695	<.001	9	view →
LUAD	Female	III,IV	+0.630	<.001	9	view →
COAD	Female	II,III,IV	+0.479	<.001	9	view →
PDAC	Female	All	−1.893	<.001	7	view →
HNSC	All	All	+0.182	.011	7	view →
OV	All	All	+0.875	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SSR1–CCRCC

Open the CCRCC breakdown →